
Wednesday, June 25

8:00~9:05 *Session 12 Molecular biology*

Moderator: Daisuke Kawauchi (Japan)
 Russel Pieper (USA)

- O-087** Transcription Factor Mediated Rescue of Glioblastoma Differentiation Failure
Peter Dirks (Canada)
- O-088** TUMOR-WIDE RNA SPLICING ABERRATIONS GENERATE ACTIONABLE PUBLIC NEOANTIGENS
Hideho Okada (USA)
- O-089** THE EVOLUTION OF THE TUMOR AND IMMUNE SYSTEM AFTER CAR T CELL THERAPY IN RECURRENT GBM
Dana Silverbush (USA)
- O-090** AUTOPHAGY MODULATES GLIOBLASTOMA CELL SENSITIVITY TO SELINEXOR-MEDIATED XPO1 INHIBITION
Russell O. Pieper (USA)
- O-091** TESTOSTERONE FUNCTIONS AS A TUMOR SUPPRESSOR IN THE BRAIN VIA ABERRANT ACTIVATION OF THE HPA AXIS, DRIVING IMMUNE SUPPRESSION
Justin D. Lathia (USA)
- O-092** REPROGRAMMING OF MYELOPOIESIS IN MUTANT IDH 1 GLIOMAS ENHANCES THE RESPONSE TO IMMUNE MEDIATED THERAPIES
Maria G. Castro (USA)
- O-094** METRNL Cytokine Drives Immune Cell Exhaustion in Tumor Infiltrating Lymphocytes by Inducing Bioenergetic Dysregulation
Michael Lim (USA)
- O-119** Bcl-xL inhibition targets senescent glioblastoma cells post temozolomide treatment to induce apoptosis
Fumi Higuchi (Japan)
- O-095** IMMUNE DEPENDENCY OF ANTI-VEGF TREATMENT EFFICACY AGAINST GLIOMA
Katrin Lamszus (Germany)
- O-096** A FULLY DIFFERENTIATED RAT BRAIN ORGANOID MODEL FOR EXPLORING GLIOBLASTOMA INVASION DYNAMICS AND THERAPY
Rolf Bjerkvig (Norway)
- O-097** Exploring Fibronectin Subtypes for Prognosis Prediction and Therapeutic Targeting in Malignant Glioma
Kyuha Chong (Korea)

9:05~10:11 *Session 13 Pediatric Neuro-Oncology*

Moderator: Annie Huang (Canada)
 Chris Jones (UK)

- O-098** Molecular Mechanisms and Developmental Pathways of Central Nervous System Germ Cell Tumors Elucidated through Whole Genome Analysis
Hirokazu Takami (Japan)
- O-099** A whole genome Nanopore sequencing analysis suggested distinct mechanisms of development in central nervous system germ cell tumors
Koichi Ichimura (Japan)
- O-100** Initiation and birth dating of medulloblastoma
Stefan M. Pfister (Germany)

- O-101 Deciphering the Epigenomic Landscape of SHH-Medulloblastoma: Regulatory Mechanisms and Therapeutic Insights
Daisuke Kawauchi (Japan)
- O-102 EPIGENETIC UPREGULATION OF SCHLAFEN11 RENDERS WNT- AND SHH- ACTIVATED MEDULLOBLASTOMAS SENSITIVE TO CISPLATIN
Manabu Natsumeda (Japan)
- O-103 Blockade of insulin signaling cooperates with PI3K inhibitors to suppress MYCN pediatric high-grade glioma growth
Sameer Agnihotri (Canada)
- O-104 GENETIC ANCESTRY SUPERPOPULATIONS REVEAL DIFFERENT PREVALENCE, OUTCOMES, AND TREATMENT ACROSS PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS FROM PBTA AND PNOC
Cassie Kline (USA)
- O-105 PHOSPHOTYROSINE INTERACTION DOMAIN-CONTAINING 1 (PID1), A GROWTH INHIBITOR IN GLIOMAS AND MEDULLOBLASTOMAS, IS A NOVEL MEDIATOR IN THE HIPPO SIGNALING PATHWAY
Anat Erdreich-Epstein (USA)
- O-106 HEAD START 4 SONIC HEDGEHOG (SHH) MEDULLOBLASTOMA: 2 YEAR FOLLOW-UP
Stephen A. Sands (USA)
- O-107 ASTROBLASTOMAS WITH BEND2 FUSION SHOWING EXTENSIVE CARCINOMA-LIKE EPITHELIAL DIFFERENTIATION MIMICKING METASTATIC ADENOCARCINOMA
Sumihito Nobusawa (Japan)
- O-108 Clinical and molecular characterization of infantile central nervous system germ cell tumors
Kohei Fukuoka (Japan)
- O-109 Single center analysis of a phase II trial of dabrafenib plus trametinib in BRAF V600 mutant pediatric low grade glioma and relapsed/refractory BRAF V600 mutant pediatric high grade glioma
Keita Terashima (Japan)

10:11~10:21 *Coffee Break*

10:21~11:21 **Session 14 Preclinical Experimental Therapeutics/Tumor Models**

Moderator: Daniel Cahill (USA)
Erik Sulman (USA)

- O-110 RAS(ON) MULTI-SELECTIVE TRI-COMPLEX INHIBITOR SHOWS SINGLE AGENT ACTIVITY AND COOPERATE WITH INHIBITORS OF EIF4A IN PRECLINICAL MODELS OF GLIOBLASTOMA
William A. Weiss (USA)
- O-111 A novel, pooled, high-throughput screening of a CNS penetrant compound library identifies potential biomarker-driven therapeutics for glioblastoma
Erik Sulman (USA)
- O-112 TARGETING AXONAL GUIDANCE DEPENDENCIES IN GLIOBLASTOMA WITH ROBO1 CAR T CELLS
Sheila Kumari Singh (Canada)
- O-113 PRECLINICAL STUDIES OF MICROBUBBLE MEDIATED NON-THERMAL FOCUSED ULTRASOUND FOR INTRACRANIAL TUMOR ABLATION
Randy Jensen (USA)
- O-114 Integrative multiomics combined with functional pharmacological profiling in patient-derived preclinical models for the identification of personalized therapeutic vulnerabilities of high-grade gliomas
Anna Golebiewska (Luxenburg)

- O-115** Designer integrin signaling blocking peptides that reprogram the immunosuppressive tumor microenvironment and vasculature improve anti-PD-1 immunotherapy in brain tumors
Bozena Kaminska (Poland)
- O-116** COLLAGEN RECEPTOR LAIR-1 MODULATES FIBROSIS, IMMUNE INFILTRATION, AND THERAPEUTIC RESPONSES IN EXPERIMENTAL MODELS OF GLIOMA
Pedro Lowenstein (USA)
- O-117** RATIONAL DESIGN OF CELLULAR THERAPIES TO OVERCOME TUMOR HETEROGENEITY AND IMMUNOSUPPRESSION IN GLIOBLASTOMA
Anoop P. Patel (USA)
- O-118** INHIBITION OF MIR-146A DECREASES PROGRESSION OF MELANOMA BRAIN METASTASIS
Frits Thorsen (Norway)
- O-120** ADC drug discovery based on the unmet medical needs
Do-Hyun Nam (Korea)
- O-121** Replication stress checkpoints in IDH mutant glioma can be selectively targeted in combination with radiation therapy
Daniel P. Cahill (USA)
- O-122** Unraveling Immune Evasion Mechanisms and Pioneering Immune Revitalization Strategies in Malignant Brain Tumors
Ying Mao (China)

11:21~11:46 **Session 15 Viral therapy 2**

Moderator: Kazuhiko Kurozumi (Japan)

- O-125** Development of a novel oncolytic herpes virus with reduced tumor swelling for malignant glioma
Tomoki Todo (Japan)
- O-126** Immunovirotherapy for Recurrent Glioblastoma using Measles Virus Strains Expressing the Toll-like receptor 2 (TLR2) agonist Neutrophil Activating Protein (NAP)
Evanthia Galanis (USA)
- O-127** EXPAND AND PULL: A NEW WAY TO BOOST THE ANTI-TUMOR RESPONSE IN GBM
Milan G. Chheda (USA)
- O-128** Suicide Gene Therapy for Brain Tumors Using SHED Expressing HSV-TK
Kazuhiko Kurozumi (Japan)
- O-129** IDH STATUS DICTATES OHSV MEDIATED METABOLIC REPROGRAMMING AFFECTING ANTI-TUMOR IMMUNITY
Balveen Kaur (USA)

11:56~12:57 **Luncheon Seminar 3 Pediatric Neuro-Oncology**
(Sponsor: Gold Ribbon Network Foundation / Aflac Life Insurance Japan Ltd.)

Moderator: Cassie Kline (USA)
James Rutka (Canada)

- LS3-1** ROBUST DETECTION, CLASSIFICATION, AND MONITORING OF PEDIATRIC BRAIN TUMORS FROM CELL-FREE DNA METHYLOMES
Paul A. Northcott (USA)
- LS3-2** ZSCAN4 mediates telomere repair in group 3 medulloblastomas and is targetable for therapeutic benefit
Aaron Diaz (USA)
- LS3-3** Generation of improved, clinically-relevant models of atypical teratoid rhabdoid tumors
James Thomas Rutka (Canada)

- LS3-4 PNO022 report: a combination therapy trial using an adaptive platform design for patients with diffuse midline glioma at initial diagnosis, post-radiation therapy, or progression
Sabine Mueller (USA)
- LS3-5 REGULATION OF GABAERGIC INTERNEURON CELL FATE IN EMBRYONIC FOREBRAIN AND TARGETING THE CELL OF ORIGIN OF DIFFUSE HEMISPHERIC GLIOMA
David D. Eisenstat (Australia)
- LS3-6 Unravelling selective, targetable dependencies in ACVR1-mutant diffuse midline glioma
Chris Jones (UK)
- LS3-7 MicroRNA CAN PROMOTE SENESENCE IN PEDIATRIC LOW GRADE GLIOMA
Charles Eberhart (USA)
- LS3-8 PNO008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA): UNIVERSITY OF CALIFORNIA SAN FRANCISCO (USA)
Michael D. Prados (USA)
- LS3-9 C19MC LEVERAGES DNA DAMAGE REPAIR PATHWAYS TO DRIVE ETMR TUMORIGENESIS
Annie Huang (Canada)
- LS3-10 OUTCOMES BY CLINICAL AND MOLECULAR RISK-FACTORS, INCLUDING NEUROCOGNITIVE LATE-EFFECTS, FOR INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED SHH MEDULLOBLASTOMA TREATED ON HEAD START 4 (HS4) CLINICAL TRIAL
Girish Dhall (USA)

13:02~13:41 **Session 16 Immunotherapy 2**
(Sponsor: NIHON SERVIER CO., LTD. MEDICAL & PATIENT AFFAIRS)

Moderator: Duane Mitchell (USA)

- O-131 DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Robert M. Prins (USA)
- O-133 RNA-BASED IMMUNOTHERAPIES TARGETING MALIGNANT BRAIN TUMORS
Duane A. Mitchell (USA)
- O-134 Preliminary results of a phase II study of stereotactic radiosurgery in conjunction with the PD-1 inhibitor Pembrolizumab for the treatment of recurrent high-grade meningioma
Nancy Ann Oberheim Bush (USA)
- O-135 INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)
Annick Desjardins (USA)
- O-136 IMMUNE PROFILING IN PERIPHERAL BLOOD PREDICTS TREATMENT RESPONSE AND SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING PD-L1 IMMUNOTHERAPY
Annette Molinaro (USA)
- O-137 PHASE 1/2 TRIAL OF A WT1 PEPTIDE-DOSING EMULSION IN CHILDREN WITH RECURRENT/REFRACTORY DIFFUSE INTRINSIC PONTINE GLIOMA, GLIOBLASTOMA, OR ANAPLASTIC ASTROCYTOMA
Naoya Hashimoto (Japan)
- O-138 p53 and PIK3R2 immunostaining status as prognostic predictive factors of autologous tumor vaccine for initially diagnosed glioblastoma
Eiichi Ishikawa (Japan)

13:41~14:06 **Session 17 Drug delivery/Other therapy**

Moderator: Rintaro Hashizume (Japan)

O-139 ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING IN CONJUNCTION WITH CARBOPLATIN/NAB-PACLITAXEL CHEMOTHERAPY FOR PATIENTS WITH FIRST RECURRENCE GLIOBLASTOMA. INITIAL RESULTS OF A PHASE 2 STUDY.

Roger Stupp (USA)

O-140 TARGETING NON-APOPTOTIC CELL DEATH IN GLIOBLASTOMA

David Allan Nathanson (USA)

O-141 Clinical Benefits of Photodynamic Therapy Using Talaporfin Sodium in Patients with Isocitrate Dehydrogenase-Wild Type Diagnosed Glioblastoma: A Retrospective Study of 100 Cases

Kazuhiro Tanaka (Japan)

O-142 ULTRASOUND-BASED BLOOD-BRAIN BARRIER OPENING WITH IMPLANTABLE ULTRASOUND AND MICROBUBBLES: PHARMACOKINETIC AND IMMUNE-RELATED IMPLICATIONS OF HOMEOSTASIS DURING RAPID REPAIR OF CAPILLARIES IN THE HUMAN BRAIN

Adam M. Sonabend (USA)

O-143 CO-DELIVERY OF PANOBINOSTAT AND siSTAT3 USING ENGINEERED M1 MACROPHAGE EXOSOMES FOR GBM RECURRENCE THERAPY

Jian Wang (Norway)

14:06~14:36 **Session 18 Epidemiology/Neuroscience**

Moderator: Stephen Sands (USA)

O-144 Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters

Elizabeth Brooks Claus (USA)

O-149 THE GENOMIC LANDSCAPE OF FAMILIAL GLIOMA

Melissa Bondy (USA)

O-146 Inflammatory Microglia Orchestrate Tumor-Neural Synaptogenesis in CNS Tumors

Dieter Henrik Heiland (Germany)

O-147 Electrophysiological and spatial profiling of glioma-infiltrated cortex reveals layer-specific neuronal population remodeling

Shawn L. Hervey-Jumper (USA)

O-148 SPATIAL SYNAPTIC CONNECTIVITY UNDERLIES OLIGODENDROGLIOMA EVOLUTION AND RECURRENCE

David R. Raleigh (USA)

14:36~14:42 **Closing remarks and handover**

Conference Chair: Koichi Ichimura (Japan), Conference Chair for ICBTRT 2027: Pim French (Netherlands)